Search results for "BOCEPREVIR"
showing 4 items of 34 documents
Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective
2012
Until very recently, treatment for chronic hepatitis C virus (HCV) infection has been based on the combination of two non-viral specific drugs: pegylated interferon-α and ribavirin, which is effective in, overall, about 40%-50% of cases. To improve the response to treatment, novel drugs have been designed to specifically block viral proteins. Multiple compounds are under development, and the approval for clinical use of the first of such direct-acting antivirals in 2011 (Telaprevir and Boceprevir), represents a milestone in HCV treatment. HCV therapeutics is entering a new expanding era, and a highly-effective cure is envisioned for the first time since the discovery of the virus in 1989. H…
Boceprevir in the treatment of chronic hepatitis C virus infection
2011
1Hepatology-Liver Transplantation Unit, Digestive Medicine Service, Hospital Universitari La Fe, and National Network Center for Hepatology and Gastroenterology Research, instituto de Salud Carlos iii, CiBeReHD Spain; 2CSiSP, Center for Public Health Research, Public Health Department, Generalitat Valenciana and Microbioloy Department/ institut Cavanilles, University of Valencia, Valencia, Spain; 3National Network Center for Biomedical Research in epidemiology and Public Health, instituto de Salud Carlos iii, CiBeReSP Spain
Health Policy Model: Long-Term Predictive Results Associated with the Management of HCV-Induced Diseases in Italy
2014
Background: This study is aimed at describing the epidemiological and economic burden that HCV will generate in the next few years in Italy. Furthermore, the impact that future anti-HCV treatments may have on the burden of disease was considered. The analysis has been developed over the period 2013-2030 from the Italian National Health Service (NHS) perspective.Methods: A published system dynamic model was adapted for Italy in order to quantify the HCV-infected population, the disease progression and the associated cost from 1950 to 2030. The model structure was based on transition probabilities reflecting the natural history of the disease. In order to estimate the efficacy of current anti…
New developments in the management of hepatitis C virus infection: focus on boceprevir
2012
Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%-50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes.